Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), sold 93,796,763 shares of the company's stock at a price of $938.43 per share on November 4, 2025. This transaction totaled approximately $88,021.98 million.
Following this sale, Lilly Endowment Inc retains 93,796,763 shares of Eli Lilly and Co. Insider transactions such as this one are reported to the SEC, providing transparency into the stock activities of company executives and board members. While significant selling activity can draw attention, it is important to note that insider sales may occur for various reasons, including diversification, tax planning, or personal financial needs.
Eli Lilly and Co operates in the pharmaceuticals industry and is headquartered in Indianapolis, Indiana. The company employs 47,000 full-time staff and focuses on the discovery, development, manufacture, and sale of pharmaceutical products. Key products include those for cardiometabolic health, oncology, immunology, and neuroscience.
As of November 8, 2025, Eli Lilly has a market capitalization of $886.2 billion, a P/E ratio of 48.13, and an EPS of 20.45. The upcoming earnings report is scheduled for August 4, 2026, with an estimated EPS of $7.70 and revenue of $17.9 billion. Investors are encouraged to examine insider activity patterns across multiple insiders and time periods when evaluating these signals.